Letter to the Editor
Sensor-augmented pump therapy (SAP) has demonstrated to improve HbA1c and reduce the frequency of hypoglycemia in patients with type 1 diabetes (T1D). Different levels of automation of insulin infusion in response to sensor readings have been introduced. [1] [2] [3] Our aim was to prospectively evaluate the additional benefits provided by SAP with predictive low-glucose suspend function (PLGS) in T1D patients experienced in the use of SAP with low-glucose suspend feature (LGS).
Thirty No changes in HbA1c were found at the end of follow-up (both 7.1 ± 0.6%). No severe hypoglycemia episodes or diabetic ketoacidosis episodes were reported. The changes found after the upgrade from LGS to PLGS are summarized in Table 1 . In the patients with impaired awareness of hypoglycemia, 45% (n = 14), Gold Score was reduced from 5.6 ± 1.1 to 4.7 ± 1.6 (P = .022), and 3 out of the 14 patients (21%) regained hypoglycemia awareness. Of the adults, 65% (n = 20) reported being less worried about hypoglycemia, mainly at night, with PLGS and all of them agreed to keep using SAP with PLGS.
Few studies have specifically addressed the advantages of PLGS in patients already experienced with the use of LGS. Biester et al 4 showed a 59% reduction in time <70 mg/dl in 6 children, as a result of an unintentional study protocol deviation. Zhong et al 5 retrospectively analyzed anonymized data from 851 users who had switched from SAP with LGS to SAP with PLGS, finding a 40% reduction in the time spent <70 mg/dl. Gómez et al 6 found a reduction in the frequency of severe hypoglycemia.
Our study has several strengths. The analysis of glycemic variability and patient-reported outcomes give a comprehensive assessment of the advantages and weaknesses of the PLGS. Testing the system in patients already benefiting from automation against hypoglycemia, with an optimal glycemic control and a low rate of hypoglycemia, has challenged the possibilities of the new system. Also, the impact of diabetes technology on sleep quality has been previously very scarcely studied.
In summary, we present a prospective study evaluating the benefits of SAP with PLGS compared to SAP with LGS, showing a reduction in hypoglycemia frequency along with an improvement in patients' fear of hypoglycemia and the sleep quality, while an optimal and stable glycemic control was maintained. 
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